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Despite its well known histological and clinical features,
Hodgkin’s lymphoma (HL) has recently been the object
of intense research activity, leading to a better
understanding of its phenotype, molecular
characteristics, histogenesis, and possible mechanisms
of lymphomagenesis. There is complete consensus on
the B cell derivation of the tumour in most cases, and on
the relevance of Epstein-Barr virus infection and
defective cytokinesis in at least a proportion of patients.
The REAL/WHO classification recognises a basic
distinction between lymphocyte predominance HL (LP-HL)
and classic HL (CHL), reflecting the differences in clinical
presentation and behaviour, morphology, phenotype,
and molecular features. CHL has been classified into
four subtypes: lymphocyte rich, nodular sclerosing, with
mixed cellularity, and lymphocyte depleted. The borders
between CHL and anaplastic large cell lymphoma have
become sharper, whereas those between LP-HL and T
cell rich B cell lymphoma remain ill defined. Treatments
adjusted to the pathobiological characteristics of the
tumour in at risk patients have been proposed and are
on the way to being applied.
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Hodgkin’s disease (HD) is a lymphoid tumourthat forms less than 1% of all de novoneoplasms occurring every year world wide.
Its diagnosis is based on the identification of char-
acteristic multinucleated giant cells within an
inflammatory milieu. These cells—termed Reed-
Sternberg (RS) or diagnostic cells—represent the
body of the tumour: they measure 20–60 µm in
diameter and display a large rim of cytoplasm and
at least two nuclei with acidophilic or amphophilic
nucleoli, covering more than 50% of the nuclear
area (fig 1A). The tumoral population also includes
a variable number of mononuclear elements—
Hodgkin’s cells (HCs)—showing similar cytologi-
cal features to RS cells and neoplastic cell variants,
each corresponding to a specific subtype of HD.
Molecular studies have recently shown that in
most if not all cases RS cells, Hodgkin’s cells, and
cell variants belong to the same clonal population,
which is derived from peripheral B and T cells in
about 98% and 2% of cases, respectively.1–8 Accord-
ingly, HD has been included among malignant
lymphomas and the term “Hodgkin’s lymphoma”
(HL) has been proposed.6 9 10
Although regarded as “diagnostic”, RS cells are
not exclusive to HL because similar elements can
be seen in reactive lesions (such as infectious
mononucleosis), B and T cell lymphomas, carcino-
mas, melanomas, and sarcomas.11 Thus, the pres-
ence of an appropriate cellular background—along
with the results of immunophenotyping—is basic
for the diagnosis. The reactive milieu, which can
form up to 99% of the total population examined,
consists of small lymphocytes, histiocytes, epithe-
lioid histiocytes, neutrophils, eosinophils, plasma
cells, and fibroblasts in different proportions,
depending on the histological subtype of HL. It is
sustained by an autocrine and/or paracrine produc-
tion of cytokines such as interleukin 2 (IL-2), IL-5,
IL-6, IL-7, IL-9, IL-10, IL-13, basic fibroblast growth
factor, transforming growth factor β1, tumour
necrosis factor α (TNF-α), and thymus and activa-
tion related chemokine.12–16 The release of these
molecules is also responsible for most of the symp-
toms recorded in patients with HL, in addition to
the ability of the neoplastic cells to escape from
growth controls and immunosurveillance. More
recently, it has been proposed that hepatic growth
factor and c-MET might constitute an additional
signalling pathway between RS cells and the reac-
tive cellular background, affecting adhesion, prolif-
eration, and the survival of RS cells.16
HISTOPATHOLOGICAL CLASSIFICATION
In 1832, Sir Thomas Hodgkin provided the first
macroscopic description of the process in a paper
entitled “On some morbid appearances of the
absorbent glands and spleen”. In 1898 and 1902,
Carl Sternberg and Dorothy Reed independently
described the typical “diagnostic” cells. In 1944,
Jackson and Parker proposed the first compre-
hensive classification of the tumour (table 1).
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Abbreviations: ALCL, anaplastic large cell lymphoma;
ALCL-HL, ALCL Hodgkin-like type; BNLI, British national
lymphoma investigation; CHL, common Hodgkin’s
lymphoma; DLBCL, diffuse large B cell lymphoma; EBER,
Epstein-Barr virus early RNA; EBV, Epstein-Barr virus; EMA,
epithelial membrane antigen; FDC, follicular dendritic cell;
FL, follicular lymphoma; HC, Hodgkin’s cell; HCRBCL,
histiocyte rich large B cell lymphoma; HD, Hodgkin’s
disease; HIV, human immunodeficiency virus; HL,
Hodgkin’s lymphoma; H&RS, Hodgkin’s and
Reed-Sternberg; IL, interleukin; LD-CHL, lymphocyte
depletion CHL; L/H, lymphocytic/histiocytic; LL, Lennert’s
lymphoma; LMP, latent membrane protein; LP-HL,
lymphocyte predominant HL; LR-CHL, lymphocyte rich CHL;
MC-CHL, mixed cellularity CHL; NHL, non-Hodgkin’s
lymphoma; NS-CHL, nodular sclerosis CHL; PCNA,
proliferating cell nuclear antigen; PCR, polymerase chain
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However, this classification was subsequently found to be
clinically irrelevant, because most patients belonged to the
granulomatous subtype and the response to treatment varied
greatly from case to case.
In 1956, Smetana and Cohen identified a histopathological
variant of granulomatous HD, which had a better prognosis
and was characterised by sclerotic changes: this variant was
termed “nodular sclerosis HD” in the classification proposed
by Lukes, Butler, and Hicks in 1964 (table 1). This last classifi-
cation, simplified at the Rye conference in 1965 (table 1) has
been used routinely over the past 35 years because of the high
interpersonal and intrapersonal reproducibility and good clin-
icopathological correlations.
In 1994, in the light of morphological, phenotypic, genotypic,
and clinical findings, HL was listed in the revised European–
American lymphoma (REAL) classification17 and subdivided
into two main types: lymphocyte predominant (LP-HL) and
common HL (CHL). CHL included the following subtypes:
nodular sclerosis (NS-CHL), mixed cellularity (MC-CHL),
lymphocyte depletion (LD-CHL), and the diffuse form of the
lymphocyte rich CHL (LR-CHL) (table 1). This approach has
finally been adopted by the recently developed World Health
Organisation (WHO) scheme (table 1), which has promoted
LR-CHL from a provisional entity to an accepted entity. In this
classification, the nodular form of LR-CHL has been included, as
proposed by the European lymphoma task force.6 18 19
It is noteworthy that HL subtyping should be performed
only in lymph node biopsies at the onset of the disease: in fact,
chemotherapy and/or radiotherapy modify the histopathologi-
cal picture by inducing a lymphocyte depleted pattern.
LP-HL
LP-HL represents 4–5% of all HL cases,20 and differs greatly
from the common type in terms of morphology, phenotype,
genotype, and clinical behaviour (table 2). The only feature
shared by LP-HL and CHL is the low number of neoplastic
cells. For a long time, after the adoption of the Lukes classifi-
cation, the tumour was also called “nodular paragranuloma”,
a designation coined by the Kiel group,21 based on the term
“paragranuloma” introduced much earlier by Jackson and
Parker. This designation intended to underline the differences
existing between this type of HL and the remaining ones.
Clinical findings
LP-HL displays features that are not generally encountered in
CHL, which makes its clinical picture closer to that of
“indolent” B cell lymphoma.22 First, it has a unimodal age dis-
tribution, with a single peak in the 4th decade, which
contrasts with the two peaks of CHL, one in the 3rd and the
other in the 7th decade.22 The disease usually affects single
cervical, axillary, or inguinal nodes rather than groups of
nodes. Bone marrow involvement is found only occasionally
during staging procedures in patients whose disease appears
to be limited to a single node22; this pattern of spread differs
from the orderly progression classically seen in CHL.23
Involvement of the thymus is most unusual, unlike the other
types of HL.22 The tumour has a very indolent course, with
prolonged disease free intervals, despite a high rate of late
relapses, which usually respond well to treatment.22 24 In addi-
tion, it can be associated with a diffuse large B cell lymphoma
(DLBCL), which has a more favourable outcome than de novo
large B cell lymphomas.22 25 In general, the prognosis is good
and specific treatment protocols are now beginning to be used;
it has even been questioned whether a patient whose disease
is restricted to a single lymph node needs further treatment.22
These clinical findings alone justify a clear cut distinction
between LP-HL and CHL, a concept that is supported by mor-
phological and phenotypic data (see below).
Morphological findings
In most instances, the growth is—at least in part—nodular (fig
1B), with the occurrence of a diffuse variant of the process being
very rare.22 26 The neoplastic population consists of large
elements, called L&H (lymphocytic/histiocytic) or popcorn
cells.22 The former term has almost completely been abandoned
in the light of the confirmed lymphoid derivation of the
tumour.2–7 Popcorn cells show nuclei resembling those of
centroblasts, with a polylobular profile, finely dispersed chroma-
tin, and small nucleoli, which are often adjacent to the nuclear
membrane (fig 1C).22 Their cytoplasmic rim is narrow and
basophilic when stained with Giemsa. Occasionally, neoplastic
elements display the features of RS cells and/or of lacunar cells
of NS-CHL and are associated with minimal sclerosis22; under
these circumstances, immunophenotyping plays a fundamental
role in the differential diagnosis between LP-HL and LR-CHL or
NS-CHL (table 2). The reactive milieu consists of small
lymphocytes with some plasma cells and epithelioid elements,
which at times become so numerous as to mimic a histiocyte
rich, large B cell lymphoma (HCRBCL).27
Progressively transformed germinal centres
Progressively transformed germinal centres (PTGCs)—first
described by Lennert in collaboration with Müller-Hermelink
in 197828—are a peculiar form of follicular hyperplasia, which
can be confused with LP-HL.
PTGCs occur in children and young adults, and these indi-
viduals reveal a slightly higher risk of developing LP-HL than
the average population. PTGCs can precede, concur with, or
follow LP-HL.21
On morphological grounds, PTGCs are two to three times
larger than reactive follicles and predominantly consist of
small lymphocytes, mainly mantle cells, intermingled with
some centroblasts and follicular dendritic cells (FDCs) (fig
1D). PTGCs can be differentiated from LP-HLs because of the
lack of popcorn elements and their cytological composition:
they are composed of a mixture of B (CD20+) and T (CD3+)
cells, histiocytes, and FDCs, which overall produce a “moth-
eaten” appearance.28 29
Phenotypic findings
The neoplastic cells have a characteristic profile, which differs
greatly from that of CHL.6 17 19 22 In particular, they are CD45+,
CD19+, CD20+, CD22+, CD79a+, J chain+/−, epithelial membrane
antigen (EMA)+/−, and CD15−. CD30 positivity is rare and, when
detected, weak. Interestingly, a certain number of extrafollicular
reactive blasts (smaller than the popcorn cells) are detected by
the anti-CD30 antibodies: in the past, they have been misinter-
preted as tumoral elements.19 Popcorn cells regularly express
Oct2 and BOB.1 (fig 1E–J).30 The transcription factor Oct2 and
its coactivator BOB.1 play a basic role in immunoglobulin
synthesis by triggering the specific gene promoter,31 and are
excellent tools for the identification of neoplastic cells in LP-HL,
in addition to their differentiation from those of CHL, which are
negative in almost all instances.30
The derivation of the tumour from germinal centres is sup-
ported by:
(1) The expression of the bcl-6 gene product (fig 1I),32 CD40
(fig 1K), and CD86 by neoplastic cells.32 33
(2) The occurrence of numerous CD4+/CD57+ T cells surround-
ing the popcorn cells, as seen in normal germinal centres and
PTGCs (fig 1F,G).34
(3) The presence of an FDC meshwork (CD21+/CD35+) within
the nodules (fig 1L).35
Kraus and Haley36 have recently reported that LP-HL is charac-
terised by Bcl-6/CD57 double stained small lymphocytes roset-
ting around typical CD20+/Bcl-6+ popcorn cells. These small
lymphocytes correspond to a subset of CD57+ T helper cells
found within the germinal centre, which coexpress Bcl-6 (B
Falini et al. Presented at the Third International Symposium on
Hodgkin’s Lymphoma, Kolne, Germany, September 18–23,
1995). They are very useful for the differential diagnosis with
PTGC, LR-CHL, and T cell rich B cell lymphoma (TCRBCL),
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which do not generally contain these double stained T cell
rosettes.36 However, a proportion of TCRBCLs may show a
pattern similar to the one observed in nodular LP-HL, support-
ing the view of Rüdiger et al that the borders between the two
tumours are not always sharp and the diagnosis needs a combi-
nation of phenotypic features, including the CD21+ FDC pattern
and the TIA-1/CD57 ratio.37 Finally, as revealed by their Ki-67
positivity, most popcorn cells are in cycle.
Genotypic findings
Further evidence indicating that the tumour is derived from
germinal centre B cells has been provided by recent molecular
studies, based on the single cell polymerase chain reaction
(PCR).1–7 These studies have shown that popcorn cells in any
given case represent monoclonal populations derived from
germinal centre B cells, owing to the consistent occurrence of
monoclonal Ig gene rearrangements and the high load of
somatic mutations within variable region genes. Ongoing
mutations are detected in about half of LP-HL cases: this
finding—not observed in CHL—identifies mutating germinal
centre cells as the precursors of the neoplastic elements.2 5 The
pattern of mutation within these gene segments suggests that
tumoral cells, their precursors, or both have been selected for
expression of functional antigen receptors.2 5
Figure 1 (A) A typical diagnostic Reed-Sternberg (RS) cell within a composite inflammatory milieu (haematoxylin and eosin; original
magnification, ×500). (B) Nodular lymphocyte predominant Hodgkin’s lymphoma (LP-HL): at low power, a neoplastic nodule can be seen as a
densely packed cellular area with a high content of small lymphocytes (Giemsa; original magnification, ×40). (C) Nodular LP-HL: at higher
magnification, some popcorn cells and one Reed-Sternberg-like element are detected among small lymphocytes (Giemsa; original
magnification, ×450). (D) Nodular LP-HL: at low magnification, a progressively transformed germinal centre looks like a nodule of LP-HL;
however, among small lymphocytes there are some centroblasts and centrocytes, but no popcorn cells (Giemsa; original magnification, ×40).
(E) Nodular LP-HL: a popcorn cell and most small lymphocytes within a nodule express the B cell marker CD79a (APAAP technique, Gill’s
haematoxylin counterstain; original magnification, ×500). (F) Nodular LP-HL: popcorn cells are surrounded by rosettes of CD3+ T cells (APAAP
technique, Gill’s haematoxylin counterstain; original magnification, ×250). (G) Nodular LP-HL: rosetting T cells largely express CD57 (APAAP
technique, Gill’s haematoxylin counterstain; original magnification, ×250). (H) Nodular LP-HL: popcorn cells express epithelial membrane
antigen (EMA) (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×250). (I) Nodular LP-HL: popcorn cells (circled)
express the bcl-6 gene product (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×250). (J) Nodular LP-HL: positivity
of neoplastic elements for the Oct2 gene product (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×300). (K)
Nodular LP-HL: popcorn cells strongly express CD40 (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×300). (L)
Nodular LP-HL: neoplastic elements are found within a delicate meshwork of CD21+ follicular dendritic cells (APAAP technique, Gill’s
haematoxylin counterstain; original magnification, ×300).
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Finally, to date, in situ hybridisation studies with Epstein-
Barr virus (EBV) early RNA 1/2 (EBER1/2) probes, in addition
to conventional Southern blot, PCR, and immunohistochemis-
try for the latent membrane protein 1 (LMP-1), have never
detected EBV in the popcorn cells of LP-HD, in contrast to the
neoplastic component of CHL.38 39 Isolated small lymphocytes
from the reactive background carry EBV infection in 25% of
cases of CHL.19
CLASSIC HD
This variant comprises about 95% of all HL cases and shows a
typical bimodal age distribution, with a peak at 10–35 years of
age and a second peak in late life.20 It is characterised by a
series of clinical, morphological, phenotypic, and genotypic
features, which are integrated by specific findings in the four
subtypes of the process (nodular sclerosis, mixed cellularity,
lymphocyte depletion, and lymphocyte rich). CHL has a
peripheral B cell derivation in approximately 98% of cases,
with the remaining ones originating from peripheral T cells.7 8
Clinical findings
CHL usually presents in the laterocervical lymph nodes, with
peripheral extranodal involvement being very rare. About 50%
of patients are in stage I or II. A mediastinal mass is seen in
most patients with NS-CHL, at times showing the characteris-
tics of “bulky” disease. Systemic symptoms—fever, night
sweats, and body weight loss—are detected in approximately
25% of patients. In contrast to earlier reports, the histological
subtype is not regarded as a major prognostic indicator. With-
out treatment, CHL has a moderately aggressive clinical
course. With the present treatments, 70–80% of cases show
long term survival. In the early stages of the disease, extended
field irradiation has been the standard for decades and results
in excellent cure rates. However, because of fatal longterm
effects, especially the high rates of second solid tumours,
extended field radiotherapy is now being abandoned by most
study groups. Instead, mild chemotherapy for the control of
occult disease is combined with involved field irradiation. In
intermediate stage CHL, where combined modality treatment
is the treatment of choice, extended field irradiation is substi-
tuted by involved field irradiation for the same reasons. In
advanced stage CHL, eight cycles of polychemotherapy (plus
additional radiotherapy for large tumour masses and residual
lymphomas) for decades has cured only 50% to 60% of
patients. The development of a new dose intensified regimen
(such as BEACOPP) for the first time has significantly
improved that prognosis. In relapsed CHL, recently published
phase III studies suggest an improvement in the relapse free
Figure 1 (continued) (M) Common Hodgkin’s lymphoma (CHL): Hodgkin and Reed-Sternberg (H&RS) cells express the CD30 molecule
both at the cytoplasmic membrane and in the Golgi area (dot-like positivity) (APAAP technique, Gill’s haematoxylin counterstain; original
magnification, ×350). (N) CD30 membrane bound positivity in an example of embryonal carcinoma (immunoperoxidase, SABC technique;
Gill’s haematoxylin counterstain; original magnification, ×200). (O) CHL: neoplastic cells show membrane bound and dot-like CD15 positivity
(APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×350). (P) CHL: H&RS cells display variable degrees of CD20
staining (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×200). (Q) CHL: staining for IRF4/MUM1 gene product
(APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×350). (R) CHL: most neoplastic cells express the Ki-67 molecule as
revealed by the Mib-1 monoclonal antibody; some small lymphocytes are also in the cell cycle (immunoperoxidase, SABC technique; Gill’s
haematoxylin counterstain; original magnification, ×500). (S) CHL: moderate Bcl-2 protein expression by H&RS cells and a ratio of small
lymphocytes (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×300). (T) CHL: most neoplastic cells show p53
overexpression (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×300). (U) CHL: H & RS show genomic Epstein-Barr
virus integration by in situ hybridisation with fluorescein labelled EBER1/2 probes (APAAP technique, Gill’s haematoxylin counterstain; original
magnification, ×300).
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survival of patients using high dose chemotherapy. For a com-
prehensive review see Diehl and Josting.40
Morphological findings
In CHL, typical Hodgkin’s and Reed-Sternberg (H&RS) cells
(fig 1A) can be easily detected: their number (from few to
many) differs from case to case. They may be associated with
peculiar cell variants and are found within an inflammatory
milieu, related to the histological subtype (see below). The
lymph node structure is largely effaced, although remnants of
normal follicles can be detected in some cases. The type of
structural alteration is indeed characteristic in NS-CHL.
Phenotypic findings
In 1982, Schwab et al described a new monoclonal antibody,
termed Ki-1, whose reactivity seemed restricted to H&RS cells
and a small subset of normal lymphocytes with perifollicular
location. However, the extensive application of the antibody
showed that it was not specific to H&RS cells, as originally
thought, but reacted with a variety of lymphoid tumours,
including a previously unrecognised category, called anaplas-
tic large cell lymphoma.41–43 Other reagents with similar char-
acteristics have also been developed,44 and these reagents were
gathered together at the third workshop on leucocyte
differentiation antigens (Oxford, UK, 1986) to form the 30th
cluster of monoclonal antibodies (CD30). The target recog-
nised by these antibodies is a glycoprotein of 120 kDa,
expressed by lymphoid elements after activation and formed
by three distinct domains (intracytoplasmic, transmembranic,
and external).11 It is encoded by a gene located at 1p36 and
represents a member of the TNF receptor superfamily.45 As
expected, its ligand (CD30L) belongs to a group of molecules
that have homology to TNF. The external domain of CD30 is
steadily cleaved by a metalloproteinase so that it can be
detected and measured.11 Surface CD30 values seem to corre-
late with the size and diffusion of the tumour at presentation,
thus representing a new possible prognostic indicator,
Table 1 Hodgkin’s lymphoma (HL) classification
schemes
1 Jackson and Parker classification Paragranuloma
2 Granuloma
3 Sarcoma Lukes and Butler classification
1 Lymphocytic and/or histiocytic, nodular
2 Lymphocytic and/or histiocytic, diffuse
3 Nodular sclerosis
4 Mixed cellularity
5 Diffuse fibrosis
6 Reticular Rye conference classification
1 Lymphocyte predominance
2 Nodular sclerosis
3 Mixed cellularity
4 Lymphocytic depletion Revised European–American
lymphoma (REAL) classification
1 Nodular lymphocyte predominance nodular/diffuse
2 Classic HL
Nodular sclerosis
Mixed cellularity
Lymphocyte depletion
Lymphocyte rich classic HL diffuse (provisional entity)
World Health Organisation scheme
1 Nodular lymphocyte predominant HL
2 Classic HL
Nodular sclerosis HL (grades 1 and 2)
Lymphocyte rich classic HL*
Mixed cellularity HL
Lymphocyte depleted HL
Unclassifiable classic HL
*This includes a nodular (common) and a diffuse (rare) form in
contrast to the REAL classification.
Table 2 Differential diagnosis between T cell rich, large B cell lymphoma
(TCRBCL), lymphocyte predominant Hodgkin’s lymphoma (LP-HL), and common
Hodgkin’s lymphoma (CHL)
Diagnostic criteria TCRBCL LP-HL Nodular/diffuse CHL
Neoplastic component
Cell distribution Dispersed Within the nodules Dispersed
L&H/L&H-like cells −/+ +/− −
RS/RS-like cells −/+ −/+ −
CD45 expression + + −
CD30 expression −* −* +
CD15 expression − − +/−
CD79a expression +/− −/+ −/+ Variable
CD20 expression +† +† −/+ Variable
BOB.1 expression + + −
Oct2 expression +‡ +‡ Rare
CD3 expression − − −/+
EMA expression +/− +/− Rare
J chain expression +/− +/− −
MIB-1/Ki-67 expression High High High
EBV − − + Variable
Ig gene rearrangement + + +§
Reactive component
T cells Numerous Moderate Variable
T cells with irregular nuclear profile +/− − −/+
Bcl-6+/CD57+ rosettes − Numerous −
Amount of TIA-1+ cells Very high Low High
Amount of CD20+ small lymphocytes Low High Low
Histiocytes Variable Some Variable
FDC − + +
Clinical findings
Stage III/IV I/II I/III
Bone marrow involvement +/− − −
Orderly progression in the spread − − +
EMA, epithelial membrane antigen; FDC, follicular dendritic cells; L/H, lymphocytic/histiocytic (popcorn); RS,
Reed Sternberg.
*Weakly positive in some instances; †negative in rare instances; ‡usually overexpressed; §in 1–2% of the
cases T cell receptor gene rearrangement.
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independent of age, race, symptoms, and bulky disease.46 The
CD30 molecule has also been proposed as a possible target for
specific antibodies conjugated with plant toxins and adminis-
tered to patients with CHL for therapeutic purposes:
preliminary studies have shown these immunotoxins to have
remarkable cytotoxic activity.47–50
On immunohistochemical analysis, both in paraffin wax
embedded and frozen sections, the antibodies against CD30
produce different types of positivity: membrane bound or
dot-like in the Golgi area (corresponding to the accumulation of
the 90 kDa proteic precursor) and diffuse (fig 1M). The first two
patterns are exclusive to lymphoid elements (fig 1M), with the
exception of embryonic carcinoma (fig 1N),11 51 whereas the dif-
fuse pattern can occur in a variety of malignant tumours other
than lymphomas, including pancreatic carcinoma, nasopharyn-
geal undifferentiated carcinoma, and malignant melanoma.44
Therefore, the immunophenotypic diagnosis of HL should
always be based on the application of a panel of antibodies,
including reagents against cytokeratins, melanoma associated
antigens, carcinoembryonic antigen, and placental alkaline
phosphatase.11 Expression of the CD30 molecule by H&RS cells
is seen in more than 98% of CHLs, although the intensity of the
immunostaining can vary from one case to another, and even
within the same case. Interestingly, the antigen is masked by
fixation (especially prolonged fixation in formalin or fixation in
B5): thus very efficient antigen retrieval techniques are required
to achieve reliable results in routine material.52
CD15 is another valuable marker for H&RS cells (fig 1O),
and is detected in about 80% of patients with CHL.42 53 CD15 is
characteristic, but not specific, for H&RS cells because it can be
detected (although rarely) in B and T cell lymphomas and in
non-lymphoid tumours. 42 53 54
H&RS cells usually lack CD45 and EMA expression,55–59
whereas B and T cell markers are seen in a proportion of cases.
In particular, CD20 (fig 1P) is found in 30–40% of CHL cases
(usually EBV negative)58 and CD79a is found even less often.60
Positivity (usually weak) for one or more T cell marker is
detected in a minority of H&RS cells in some cases.61 62 Under
these circumstances, single cell PCR studies have so far shown
T cell receptor (TCR) gene rearrangement in only three
instances, with clonal Ig gene rearrangements occurring in
most CHL cases with T cell marker expression.8 63 In contrast to
that seen in LP-HL, the elements of CHL show variable expres-
sion of the Bcl-6 molecule (B Falini et al. Third International
Symposium on Hodgkin’s Lymphoma, Kolne, Germany, Sep-
tember 18–23, 1995). In addition, they are usually positive for
the PAX 5 and MUM 1 gene products (BSAP and IRF4, respec-
tively) and negative for BOB.1 and Oct2 (fig 1Q).7 8 64
Antibodies against the nuclear associated antigens Ki-67
(fig 1R) and proliferating cell nuclear antigen (PCNA) stain
most H&RS cells, suggesting that a large number of neoplastic
cells enter the cell cycle.65 66 However, in spite of this, tumour
cells do not rapidly overwhelm the reactive component.65 66
This phenomenon has found a satisfactory explanation in the
studies of Leoncini and co-workers, who have shown that
H&RS cells have a defect in cytokinesis.67–70 In fact, only a
minority of the cycling elements undergo effective mitosis,
and a proportion of the cells that do not enter into the cell
cycle undergo apoptosis, a step partly regulated by the bcl-2
and p53 gene products.67–70
Recent studies have suggested that phenotypic findings
might have some prognostic relevance. In particular, the value
of the following parameters was assessed in the course of a
restrospective analysis based on 1751 patients with HL: CD30
expression, CD15 positivity, CD20 staining, age, sex, histotype,
stage, B cell symptoms, haemoglobin concentrations, and the
erythrocyte sedimentation rate. CD15 negative patients had a
higher incidence of relapses (p = 0.0022) and a lower survival
rate (p = 0.0035), independent of the remaining prognostic
indicators. Similar figures were seen in CD20 positive cases.71
Although interesting, these data need to be re-evaluated
because it must be confirmed that the CD15− tumours were
not anaplastic large cell lymphomas (ALCLs) and that the
CD20+ ones were not TCRBCLs.20
On prognostic grounds, it has also been proposed that
chemoresistance and the tendency to relapse are influenced by
the expression of Bcl-2, p53, p21, and PCNA (fig 1S,T).72 73 In
general, tumours with H&RS cells showing expression or
overexpression of one or more of these molecules seem to have
a poor response to the treatment and/or short survival time.
Genotypic findings
The origin of the RS cells of HD has long been a mystery.74 As
previously discussed in the LP-HL section, micromanipulation
of single RS cells from tissue sections and PCR analysis of the
cells for rearranged Ig genes have shown that most of both
LP-HL and CHL cases represent clonal populations of B cell
lineage.1–7 In contrast to that seen in LP-HL, ongoing
mutations are not detected in CHL.7 Based on the results
obtained in a small series of cases, emphasis was instead given
to the occurrence of mutations resulting in stop codons within
originally functional variable region gene rearrangements.5
Such mutations are expected to occur in variable region genes
of germinal centre B cells, but under physiological conditions
“crippled” germinal centre cells (incapable of functional anti-
body expression) rapidly undergo apoptosis. RS cells might
also have other mutations that can be crippling but may not be
easy to find (for example, replacement mutations interfering
with antigen binding or heavy and light chain pairing).5 How-
ever, by analysing a large number of cases, Marafioti et al have
recently found that crippling mutations are absent from 75%
of CHLs, indicating that crippling mutations cannot be
responsible for the general absence of the Ig transcripts,7
which might be the result of downregulation of the synthesis
of the transcription factors BOB.1 and Oct2 (see above).7 8 As
mentioned in the previous section, the unusual occurrence of
patients with CHL who have clonal TCR gene rearrangements
has been reported independently by two groups.8 63 Recently,
some studies have pointed to the possibility that the nuclear
transcription factor NFκB is involved in the protection of
H&RS cells from apoptosis, which would be expected because
of their inability to produce immunoglobulins.75 The persistent
activation of NFκB in H&RS cells might be caused by defects
in members of the IκB family, which are the natural inhibitors
of NfκB,75–78 or by the aberrant activation of IκB kinase.79 In
contrast, despite the frequent expression/overexpression of
p53 by neoplastic cells, no mutations of exons 4–8 of the p53
gene have been detected by H&RS cell micromanipulation,
DNA amplification, or sequencing.80
The search for the ALCL associated t(2;5)(2p23;5q35)
translocation and/or NPM/ALK hybrid gene products is
usually negative, with a few reported exceptions in the
literature,81 82 although these reports have not be confirmed in
larger series, independent of the technique used (Southern
blotting, reverse transcriptase–PCR, and immunohisto-
chemical testing with anti-ALK specific antibodies).58 83–93 This
negativity is relevant for the differential diagnosis between HL
and ALCL in problematic cases.
No specific cytogenetic abnormalities have been reported in
CHL because aberrations vary from one case to another, with
frequent intraclonal variability, thus suggesting chromosomal
instability.94 Some tumours show 14q alterations, as seen in B
cell lymphomas, but without the occurrence of the t(14;18)
translocation.94
EBV studies reveal viral integration in the genome of CHL
tumour cells in a variable proportion of patients (20–80%),
depending on the histotype. In particular, in Western
countries, 20–40% of NS and LD cases and 50–75% of MC
cases show expression of LMP-1 and/or EBER1/2, (fig 1U) but
not EBV encoded nuclear antigen 2, thus showing a pattern
characteristic of latency type II EBV infection.95 96 Interest-
ingly, these figures can vary greatly according to the
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geographical area examined, as recently shown by Leoncini
and co-workers, who found significant differences in the inci-
dence of EBV between patients with CHL from Kenya and
Italy (92% v 48%) matched for age and histotype.97 The type of
EBV strain also varies between different geographical areas; in
developed countries strain 1 prevails, whereas strain 2 is most
prevalent in developing countries.98 HLs that are positive for
EBV at diagnosis are usually also positive at relapse, with per-
sistence of the same EBV strain.99 The exact role of EBV in the
pathogenesis of human immunodeficiency (HIV) negative
CHL (transforming agent as suggested by LMP-1 expression
or cofactor for the maintenance of malignant growth?) is still
open to question (for seropositives see below).39
NODULAR SCLEROSIS
Morphological findings
NS is the most frequent subtype of CHL in Italy and the USA,
where it corresponds to 75–80% of all HL cases; however, the
incidence of these subtypes varies greatly among other
geographical areas.100–102 As stated by Lukes et al in 1966, the
Figure 2 (A) Nodular sclerosing common Hodgkin’s lymphoma (NS-CHL): the normal lymph node structure is largely effaced because of a
nodular growth; the nodule is surrounded by thick collagen bands originating from the capsule (haematoxylin and eosin; original
magnification, ×40). Inset: birefringence of collagen bands (polarised light microscopy; original magnification, ×20). (B) NS-CHL: scattered
lacunar cells can easily be seen within one nodule (haematoxylin and eosin; original magnification, ×300). Inset: cytological details of a
lacunar cell (Giemsa; original magnification, ×800). (C) NS-CHL: so called cellular phase; note the nodularity of the growth (haematoxylin and
eosin; original magnification, ×80). (D) NS-CHL: so called syncytial variant; note the cohesive growth pattern of neoplastic cells (haematoxylin
and eosin; original magnification, ×400). (E) NS-CHL: an example of grade II tumour; note the content of neoplastic cells within the nodule,
which covers more than 25% of the examined area (haematoxylin and eosin; original magnification, ×300). (F) An example of anaplastic large
cell lymphoma of the Hodgkin-like type (ALCL-HL): the tumour consists of nodules partly surrounded by collagen bands (haematoxylin and eosin,
original magnification, ×20).(G) ALCL-HL: at higher magnification it can be seen that the collagen bands are almost exclusively formed by
neoplastic cells (Giemsa; original magnification, ×300). (H) ALCL-HL: typical intrasinusoidal diffusion of neoplastic cells as shown by CD30
staining (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×200). (I) ALCL-HL: ALK protein expression by neoplastic
cells (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×400). (J) Primary mediastinal large B cell lymphoma
(PMLBCL): neoplastic cells sometimes have multiple nuclei, show a wide rim of clear, fragile cytoplasm, and elicit a stromal reaction with
compartmentalisation (Giemsa; original magnification, ×300). (K) PMLBCL: neoplastic cells express the CD30 molecule (APAAP technique,
Gill’s haematoxylin counterstain; original magnification, ×300). (L) Mixed cellularity common Hodgkin’s lymphoma (MC-CHL): Hodgkin and
Reed-Sternberg (H&RS) cells are easily identified; they are found with a cellular milieu consisting of small lymphocytes, some plasma cells,
histiocytes, and granulocytes (haematoxylin and eosin; original magnification, ×350). (M) MC-CHL: an example of a mummified cell (arrow)
(haematoxylin and eosin; original magnification, ×350).
168 Pileri, Ascani, Leoncini, et al
www.jclinpath.com
 o
n
 O
ctober 30, 2019 at Universitr degli Studi di Siena. Protected by copyright.
http://jcp.bmj.com/
J Clin Pathol: first published as on 1 M
arch 2002. Downloaded from
 
tumour is characterised by: sclerosis, lacunar cells, and nodu-
lar pattern.
Sclerosis
Fibrotic phenomena always occur in NS-CHL: they more often
correspond to the formation of broad collagen bands, which
originate from a regularly thickened lymph node capsule (fig
2A) and subdivide the lymphoid parenchyma into large nod-
ules, at times visible at gross examination. Fibrotic tissue dis-
plays a typical birefractive green colour at polarised light
microscopy (fig 2A, inset), a finding never seen in LD-CHL.
Lacunar cells
These cells are characteristic of NS-HL. Lukes et al originally
described them as large elements with polylobular nuclei, small
to medium sized nucleoli, and a wide rim of clear or slightly aci-
dophilic cytoplasm, which is very sensitive to formalin fixation.
This last factor causes perinuclear condensation of the
cytoplasm, which remains connected to the cell membrane via
some narrow filaments, forming empty “lacunar” cytoplasmic
spaces (fig 2B). In fact, lacunar cells display a much higher
degree of pleomorphism than was originally thought: they may
be unilobular, multilobular and/or show huge nucleoli, which
are indeed similar to those of typical RS cells. This morphologi-
cal variability seems to depend on the characteristics of the
inflammatory component present in each case.103 Although
lacunar cells are easily detected, H&RS cells are rare and their
identification may involve a long search. Finally, it should be
stressed that some neoplastic elements appear to be “mummi-
fied” because of apoptotic changes.
Nodular pattern
The nodules, which should be detected in at least part of the
lymph node involved, can contain foci of necrosis and can be
very variable in terms of inflammatory cell component (from
lymphocyte predominance to lymphocyte depletion).
NS-CHL: cellular phase
In NS-CHL, the amount of collagen fibres varies greatly from
one case to another. In the so called cellular phase, there is a
clear cut tendency to nodule formation without overt collagen
band deposition (fig 2C). However, there are typical lacunar
cells, often located at the periphery of the nodules or around
residual follicles. The reactive component mainly consists of
small lymphocytes bearing the phenotype of mantle B cells
(CD20+, CD79a+, CD5+, IgM+, IgD+, CD3−).104 105 The secretion of
cytokines by neoplastic cells is currently believed to cause the
progressive attraction of T cells, histiocytes, plasma cells, and
Figure 2 (continued) (N) MC-CHL: the tumour has a patent interfollicular location; a spared follicle with Castleman-like features can be seen
(haematoxylin and eosin; original magnification, ×150). (O) MC-CHL: the tumour contains reactive epithelioid cells (haematoxylin and eosin;
original magnification, ×300). (P) Peripheral T cell lymphoma not otherwise specified with a high content of epithelioid cells (so called Lennert’s
lymphoma): lymphoid elements show variation in size and shape (haematoxylin and eosin; original magnification, ×400). (Q) T cell rich,
histiocyte rich large B cell lymphoma (TCRBCL): neoplastic cells strongly express the CD79a molecule (APAAP technique, Gill’s haematoxylin
counterstain; original magnification, ×300). (R) TCRBCL: reactive T cells and histiocytes are stained by the anti-CD3 antibody (APAAP
technique, Gill’s haematoxylin counterstain; original magnification, ×150). (S) TCRBCL: reactive T cells and histiocytes are stained by the
anti-CD68 antibody (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×150). (T) Lymphocyte depleted common
Hodgkin’s lymphoma (LD-CHL), fibrotic variant: rare neoplastic cells are surrounded by thick collagen bands with a haphazard organisation,
some histiocytes and scanty lymphocytes (haematoxylin and eosin; original magnification, ×400). (U) LD-CHL, sarcomatous variant: H&RS cells
are quite numerous; there is a certain degree of fibrotic reaction; small lymphocytes are exceedingly rare (haematoxylin and eosin; original
magnification, ×350). (V) Lymphocyte rich common Hodgkin’s lymphoma (LR-CHL): mononuclear and diagnostic neoplastic elements are found
within a cellular milieu mostly consisting of small lymphocytes (haematoxylin and eosin; original magnification, ×350). (W) LR-CHL: neoplastic
cells express CD15 (APAAP technique, Gill’s haematoxylin counterstain; original magnification, ×300). (X) CHL: typical example of bone
marrow involvement; note the fibrotic reaction, and the presence of H&RS cells (haematoxylin and eosin; original magnification, ×300).
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eosinophils, which give rise to nodules replacing the
pre-existing follicles and produce the typical pattern of
NS-CHL. Within the nodules, there are numerous FDCs, which
seem to represent a favourable prognostic indicator.106 107
NS-CHL: syncytial
The term “syncytial” NS-CHD was coined by Butler in 1983
and then reproposed by Strickler et al in 1986.108 This variant is
thought to form 16% of all NS-CHL cases,109 and to run a more
aggressive clinical course,102 109 as suggested by the occurrence
of mediastinal bulky disease and stage III/IV in 88% of the
patients. At light microscopy, it is characterised by large sheets
of neoplastic cells (partly with a lacunar appearance), which
may undergo central necrosis (fig 2D).108 In the past, similar
cases have been diagnosed as non-Hodgkin’s lymphoma,
metastatic melanoma, carcinoma or sarcoma, thymic carci-
noma, or germ cell tumour. The differential diagnosis requires
the application of an adequate panel of antibodies, which
allows the identification of the characteristic phenotype of the
tumoral cells: CD3−, CD15+, CD20−/+, CD30+, CD45−, CD79a−,
cytokeratin negative, PLAP−, protein S-100−, HMB.45
melanoma associated antigen negative, EMA−, and ALK−.
Histological grading of NS-HL
The British national lymphoma investigation (BNLI) group
has repeatedly proposed that NS-CHL should be subclassified
into two grades: grade II tumours seem to represent 15–25% of
all NS-CHL cases and to run a more aggressive clinical
course,104 110 111 a finding not confirmed by all studies.106 112 113 In
the recently developed WHO scheme, the BNLI grading
system has been maintained to test its real prognostic value on
larger series.6 It is based on the degree of cellularity of the
nodules, the amount of sclerosis, and the number and atypia
of neoplastic cells. The term grade II is applied to cases show-
ing one of the three following patterns:
(1) More than 25% of the nodules have a cellular composition
consistent with the pleomorphic or reticular subtype of
NS-CHL/LDV (fig 2E).
(2) More than 80% of the nodules show a fibrotic or fibrohis-
tiocytic composition.
(3) More than 25% of the nodules contain numerous large
bizarre or anaplastic cells, in the absence of depletion of the
reactive small lymphoid component.
Differential diagnosis
Anaplastic large cell lymphoma
The borders between HL and ALCL are not always sharp: this
had led to the creation of the category of ALCL-Hodgkin’s like
(HL), which presents in about 85% of cases with a mediastinal
mass and stage II disease.17 55 87 92 114–118 On practical grounds,
this distinction is relevant because ALCL can be cured in 80%
of cases by the administration of third generation chemo-
therapy regimens, whereas HL usually requires different
therapeutical approaches.115 The problems in the differential
diagnosis result from the fact that ALCL-HL shares architec-
tural and cytological features with NS-CHL, including the
fibrotic reaction and nodule formation (fig 2F,G). In our
experience, the diagnosis of ALCL-HL should be considered
only in those cases that have nodules consisting almost exclu-
sively of basophilic blasts, with a minimal reactive cell compo-
nent, which also display the phenomenon of intrasinusoidal
spreading (fig 2H).116–118 When these morphological criteria are
applied, most of the cases in the past diagnosed as ALCL-HL
would be now reclassified as NS-CHL (grade II or syncytial)
and might tentatively be termed “ALCL-like Hodgkin’s
disease”.92 Immunohistochemistry and molecular biology
largely contribute to the differential diagnosis between HL
and ALCL (table 3). In problematical cases, the expression of
CD15, possibly in conjunction with positivity for B cell mark-
ers, and the lack of TCR gene rearrangements and ALK protein
favour HL, whereas negativity for CD15, the expression of T
cell markers and/or ALK protein, and the presence of TCR gene
clonal rearrangements or the NPM/ALK hybrid gene support
the diagnosis of ALCL (fig 2I). Cases that cannot be resolved
by the combination of cell morphology, phenotype, and
molecular data should be regarded as “unclassifiable” and
submitted to a second biopsy or a treatment equally effective
for ALCL and HL.6
Primary mediastinal (thymic) large B cell lymphoma
Primary mediastinal large B cell lymphoma (PMLBCL) is a
distinct clinicopathological entity, which makes up about 2.4%
Table 3 Differential diagnosis between anaplastic large cell lymphoma
Hodglin’s-like (ALCL-HL) and classic Hodgkin’s lymphoma (HL)
ALCL-HL HL
Morphological characteristics
Neoplastic component Usually cohesive Usually dispersed
Reactive component Often minor Usually prevalent
Reed-Sternberg cells May be present Always present
Intrasinusoidal diffusion Typical Exceptional
Molecular characteristics
CD30 + +*
CD45 +/− −
CD15 −/+ +/−
EMA +/− rare
CBF.78 + (80–90%) −/+ (rare cells)
BHN.9 + (60%)† − (5%)
CD3 −/+‡ 10%
T cell rosettes − +/−
p53 −/+ +
EBV −/+ + or +/−
Clonal TCR gene rearrangement + ¶
Clonal Ig gene rearrangement − +
PAX-5 gene product/BSAP − +
t(2;5)/ALK protein +§ −
*The intensity of immunostaining may vary within the same case; †results can vary depending on the fixative
used; ‡membrane bound and/or dot-like positivity; §some cases with morphology and phenotypic profile
consistent with ALCL-HL (including BSAP negativity) can lack t(2;5)/ALK protein expression: these cases need
further studies to assess their definitive inclusion among anaplastic large cell lymphomas; ¶in 1–2% of the
cases T cell receptor gene rearrangement occurs.
EBV, Epstein-Barr virus; EMA, epithelial membrane antigen; TCR, T cell receptor.
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of malignant lymphomas,119 and more often affects young
women.6 17 120–122 The presence of a certain number of T cells,
eosinophils, and RS-like elements, together with sclerosis,
possible nodularity, and frequent CD30 expression by neoplas-
tic cells,123 124 may lead to a misdiagnosis of HL (fig 2J,K); the
differentiation between the two processes becomes even more
problematical in small biopsies obtained during mediastinos-
copy or mini-thoracotomy. PMLBCL cells regularly express B
cell markers (CD19, CD20, CD22, and CD79a), and in about
75% of instances the recently discovered MAL protein,125
although they are negative for CD15; these findings are useful
for the differential diagnosis with HL.
Undifferentiated nasopharyngeal carcinoma
This variant occurs in young patients, producing early
metastatic involvement of laterocervical nodes, which are the
usual site of biopsy. On morphological grounds, neoplastic
cells can resemble H&RS cells and give rise to nodular growth
with sclerosis, plasmacytosis, and eosinophilia. Because the
primary tumour may remain occult, morphological features
can contribute to a misdiagnosis of NS-CHL.126 127 However,
immunohistochemistry allows the straightforward differen-
tiation of undifferentiated nasopharyngeal carcinoma from
HL by showing positivity of the neoplastic cells for cytokerat-
ins, EMA, and LMP-1. Positivity for LMP-1 results from the
regular integration of EBV into the genome of the tumour
cells, as confirmed by in situ hybridisation with EBER1/2
probes and PCR techniques.
Mixed cellularity
This histotype was originally described by Lukes et al as inter-
mediate between LP and LD-CHD. Later, Lukes included in this
category all the cases that according to his criteria remained
unclassified, transforming it into a “basket”.
About 15–25% of CHL cases belong to this category. The
histological picture is characterised by diffuse growth with a
frequent paracortical location. The capsule is not often
involved and necrosis seldom occurs. The term MC-CHL
reflects the cellular composition of the reactive milieu, which
consists of plasma cells, epithelioid histiocytes, eosinophils,
and T cells (CD3+, CD57−), which form rosettes around
neoplastic elements (fig 2L). The tumour cells correspond to
H&RS cells, and are numerous and easy to find, without lacu-
nar or popcorn variants. Some neoplastic elements, as in the
NS subtype, appear to be “mummified” because of apoptotic
changes (fig 2M).
Morphological variants of MC
Interfollicular variant
This variant is rarely seen and probably represents partial
lymph node involvement by HL. It is characterised by the
occurrence of numerous H&RS cells around reactive follicles,
which display germinal centres either in the second phase of
development128 or in regressive transformation (fig 2N). These
germinal centres usually resemble those seen in hyaline-
vascular Castleman’s disease and are probably related to the
release of cytokines, such as IL-6,129 by H&RS cells.130 This
unusual variant of MC-HL should be taken into consideration
to avoid possible confusion with follicular hyperplasia or Cas-
tleman’s disease.128 131
Epithelioid cell rich variant
This variant is relatively common and shows a prominent epi-
thelioid cell reaction with granulomata formation and
occasional Langhans cells (fig 2O). In this context, typical
H&RS cells are always detected, at times after a laborious
search. It should be differentiated from the so called Lennert’s
lymphoma (LL) (fig 2P) because of the dramatic differences in
terms of treatment between the two entities.104 132
Differential diagnosis
Lennert’s lymphoma
LL is a peripheral T cell lymphoma with a high content of epi-
thelioid elements and some blasts resembling RS cells.17 Some
of the past cases diagnosed as atypical HD correspond to per-
ipheral T cell lymphomas with a high content of epithelioid
elements.103 The following elements are of paramount import-
ance for the recognition of LL: (1) pronounced irregularity of
the nuclear profiles of the lymphoid component, as opposed to
the regular nuclear outline of reactive lymphocytes in HL.133
(2) The phenotypic profile of the atypical population, which is
CD3+, CD45+, occasionally CD30+, and CD15−, although some
cases can partially lack T cell markers.54 134 135 (3) Higher
mitotic index.136
T cell/histiocyte rich large B cell lymphoma
TCRBCL, first described in 1984,137 is an aggressive tumour,
usually presenting in stage III–IV with splenomegaly, bone
marrow involvement, and mesenteric lymphadenopathy—
findings that are rare at the onset of HL.138 Table 2 summarises
the main differences between HL and TCRBCL (fig
2Q).27 37 139–144
Lymphocyte depletion
This variant is very rare, accounting for about 1% of HL cases,
and shows the worst clinical behaviour and prognosis. In most
instances, it presents in stage III–IV, with B cell symptoms and
bone marrow involvement being detected in 50% of
cases.145 146 At microscopic examination, it is characterised by
paucity of the lymphoid component, absolute or relative
abundance of RS cells, and variable fibrotic reaction.
According to Lukes and Butler, two subtypes of LD-HL can be
distinguished: fibrotic and reticular/sarcomatous.
Fibrotic variant
This results in complete effacement of the nodal structure
with possible capsule preservation. At microscopic examina-
tion (fig 2T), it shows the following distinctive features: (1)
low cellular density with scarce, although variable, amounts of
small lymphocytes; (2) prominent diffuse reticulin fibre
formation without organised birefringent collagen bands,131
which tends to include single neoplastic elements and is asso-
ciated with the deposition of amorphous material (precolla-
gen) around sinusoids; (3) a high variability in the number of
H&RS cells, the detection of which sometimes requires a long
and labourious search.
At low power, the histopathological picture can resemble
the depletion phase of HIV lymphadenopathy133; therefore,
careful node examination is needed to make a firm
diagnosis.147
Reticular or sarcomatous variant
This is characterised by extremely large numbers of H&RS
cells, some of which appear to be “mummified” (fig 2U). The
growth results in diffuse effacement of the normal lymph
node structure; small lymphocytes, plasma cells, histiocytes,
and granulocytes are scanty; foci of necrosis are usually
encountered, although their extent varies from one case to
another.
Differential diagnosis
As a result of the extensive application of immunohistochem-
istry and molecular biology techniques, it is now evident that
most of the cases diagnosed in the 1970s and early 1980s as
sarcomatous LD-CHL were in fact examples of ALCL,146–148 per-
ipheral T cell lymphoma,149 TCRBCL, PMLBCL,150 or the syncy-
tial variant of NS-CHL. In our experience, the differential
diagnosis should also include some non-lymphoid tumours,
such as inflammatory fibrosarcoma,151 152 atypical Langerhans
cell histiocytosis, inflammatory and giant cell malignant
fibrous histiocytoma,153 lymphocyte rich well differentiated
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lyposarcoma,154 and undifferentiated nasopharyngeal carci-
noma. Under these circumstances, immunophenotyping is
essential for a correct diagnosis.
Lymphocyte rich classic Hodgkin’s lymphoma
Several reports have underlined the existence of HL cases with
a lymphocyte predominant background, but differing from
the prototypic description of LP-HL because of the presence of
some eosinophils, sclerosis, typical H&RS cells, or aberrant
phenotypic features, such as the expression of CD30 and
CD15.21 35 100 155 156 In 1994, the ILSG included in the REAL
classification a provisional entity called lymphocyte rich com-
mon Hodgkin’s disease”, which was thought to have a diffuse
growth pattern in most instances (table 1).17 Following two
workshops held by the European Association for Haematopa-
thology in 1994 and the European lymphoma task force in
1995, the existence of LR-CHL has been accepted and
expanded by the recognition of two subtypes of the tumour—
nodular and diffuse (fig 2V—which should be differentiated
from LP-HL and TCRBCL (table 2).19 37 138 157 158
On morphological grounds,19 most LR-CHL cases are
characterised by a nodular background, with admixed histio-
cytes and absent neutrophils and eosinophils closely resem-
bling nodular LP-HL, particularly at low power. Furthermore,
a varying proportion of the neoplastic cells can exhibit
features of popcorn elements. However, in contrast to LP-HL,
many lymphomatous cells have the cytomorphological fea-
tures of classic H&RS cells, and the nodular structures
frequently show small germinal centres at their periphery.
Focal areas of sclerosis can sometimes be seen.
At phenotypic analysis,19 the neoplastic cells usually express
CD30 and CD15. CD20 and CD79a positivity is found in 32.5%
and 8.7% of cases, respectively—figures that are much lower
than those observed in LP-HL. In addition, there is a complete
absence of J chain in all instances and a weak expression of
EMA in only a few cases. About 50% of the examples of
LR-CHL harbour EBV positive H&RS cells. The reactive
component consists of abundant mantle B cells, with surface
IgD and IgM expression, and variable amounts of CD3+ T cells,
which produce rosettes around neoplastic elements, but
seldom express CD57. CD21 immunostaining reveals a loose,
ill defined meshwork of FDCs, which becomes much denser
and sharper around the small residual germinal centres, when
present.
The clinical characteristics of this variant of CHL, which
accounts for about 6% of all HL cases,26 71 has been the object
of several studies, including those promoted by the inter-
national project on lymphocyte predominant Hodgkin’s
disease and the German Hodgkin’s lymphoma study
group.19 71 These studies have shown that patients with
LR-CHL differ from those with NS-CHL or MC-CHL: they are
usually older than 50 and display a higher incidence of stages
I–II and a subdiafragmatic location. In contrast, they rarely
have bulky disease, B cell symptoms, or mediastinal or extran-
odal involvement. Thus, the clinical profile of LR-CHL is closer
to that of LP-HL, although it has a lower frequency of stages
I–II and splenic infiltration is more common. When compared
with other types of CHD, LR-CHL gives rise to more frequent
late relapses, although these do not behave aggressively.
Owing to its peculiar clinicopathological features, LR-CHL
has been quoted as an accepted entity in the recently
developed WHO scheme.6
Unclassifiable HL
In cases with lymph node partial involvement, small amounts
of tissue available, or extranodal location, the classification of
HL can be difficult or even impossible. In the past, these prob-
lematical cases were usually included in the MC subtype.
Because it is useful to keep the subtypes of HD as homogene-
ous as possible for prospective clinicopathological studies,
both the REAL classification and the WHO scheme list cases
with ambiguous features or insufficient bioptic material as HL
unclassified.
EXTRANODAL INVOLVEMENT BY HL
Although the onset is typically nodal, HL can secondarily
affect extranodal organs and tissues. The criteria for the diag-
nosis of HD at extranodal sites vary greatly depending on the
clinical history and the type of tissue involved. In fact, in nee-
dle biopsies taken from the bone marrow (fig 2X) and liver
during staging procedures, the diagnosis of HL can confidently
be made according to “minimal criteria”; that is, by the detec-
tion of HC in the appropriate cellular milieu.133 In contrast, the
diagnosis of HL at other extranodal sites needs the recognition
of typical “diagnostic” cells and appropriate phenotypic mark-
ers, especially in patients with no previous history of HD.
TREATMENT RELATED HISTOLOGICAL CHANGES
Relapses of HL at previously treated sites may show morpho-
logical findings that totally differ from those seen at the time
of disease presentation. Under these circumstances, the histo-
logical picture is characterised by numerous atypical Hodg-
kin’s cells, rare RS cells, and severe lymphocyte depletion,
which can make the differentiation from a diffuse large cell
lymphoma difficult.103 159
In patients with bulky disease, a residual mass is often
detected after chemotherapy and radiotherapy, challenging
the efficacy of the administered treatment. In our experience,
histological examination of the residual mass frequently
shows a fibrotic reaction with sclero-jaline changes and
epithelioid cell palisades around necrotic foci, but no active
tumour.
Chemotherapy and radiotherapy can produce toxic damage
in organs not primarily involved in the process, such as
postradiation interstitial pneumonitis, thyroid fibrosis, cardio-
myopathy, or bone marrow aplasia. In addition, patients
treated for HL show an increased risk of developing acute leu-
kaemias, malignant lymphomas, and more rarely non-
lymphoid tumours. This concept especially applies to individu-
als who have undergone MOPP chemotherapy.103 In general,
necropsies performed on subjects with a previous history of
HL often show that the cause of death was a treatment related
complication in the absence of detectable residual disease.103
RELATIONS BETWEEN HL AND AIDS
HIV positive patients are more at risk than the normal popu-
lation of developing HL, especially of the LD or MC
subtype.160 161 At presentation, the tumour frequently shows
extensive subdiafragmatic and extranodal involvement,
whereas a mediastinal mass is less common than in HIV
negative individuals.162 Liver and bone marrow lesions may be
detected in the absence of splenic colonisation. Analogously,
skin and lung infiltrates can occur without regional or medi-
astinal node involvement. In general, HL behaves differently in
HIV positive patients than in HIV negative subjects, showing
diverse dissemination,103 a more aggressive clinical course, and
worse prognosis, thus requiring specific therapeutic
protocols.163 Neoplastic elements in HIV positive HL are more
often CD20+ and Bcl-6−/syn-1+ (CD138/syndecan-1). This last
finding differs from that usually seen in HIV negative LP-HL
(which is regularly Bcl-6+/syn-1−) and CHL (which is
characterised by a mixture of Bcl-6−/syn-1+ and Bcl-6+/syn-1−
RS cells).164 In addition, most if not all HIV positive HL cases
display positivity of neoplastic cells for EBV, as shown by
LMP-1 expression and in situ hybridisation studies. This
observation suggests an active role for EBV in the process of
lymphomagenesis in HIV positive HL,165 especially in the light
of the well known transforming ability of LMP-1.166 167 In par-
ticular, in 89% of HIV positive cases (v 32% of the seronegative
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ones), the LMP-1 gene shows a 30 bp deletion, which prolong
the half life of LMP-1 and allows its accumulation in infected
cells.165 168
ASSOCIATION OF HL WITH NON-HODGKIN’S
LYMPHOMA
The occurrence of HL and a synchronous or metachronous
form of non-Hodgkin’s lymphoma (NHL) in the same patient
is rare. The most frequent combination of the two is a DLBCL
that develops after LP-HL.22 26 169–175 However, CHL has also been
reported in conjunction with different types of NHL, including
follicular lymphoma (FL), DLBCL, B cell chronic lymphocytic
leukaemia, and even peripheral T cell lymphoma.176–192
There are three possible explanations for the occurrence of
this association: (1) both neoplasms arise coincidentally from
two unrelated lymphoid elements; (2) the HL progresses from
a previous lymphoma; or (3) both lymphomas derive from a
common precursor cell. For a long time, no reliable answer
could be given to these challenging questions. However, in the
past few years, the introduction of single cell PCR has allowed
the molecular analysis of some cases showing simultaneous or
subsequent occurrence of HL and NHL. Former reports on the
subject suggested a direct progression from NHL to HL (either
classic or lymphocyte predominant).172–175 185 187 188 Three more
recent contributions, however, have revealed that the two
tumoral components may stem from the same precursor
cell.190–192 In particular, these contributions focused on cases
that showed either the simultaneous occurrence of FL190 or
DLBCL192 and CHL, or the development of CHL in patients with
a previous history of FL191 or TCRBCL.190 In all these cases, NHL
cells and H&RS cells displayed the same monoclonal Ig gene
rearrangements, in addition to the presence of somatic muta-
tions, a finding which further strengthens the concept that
H&RS cells are derived from mature germinal centre B cell
elements.
ADDENDUM
After the completion of the present review article, an interest-
ing contribution appeared in the literature focusing on the
differences of PU.1 expression in LP-HL and CHL. This
transcription factor, which is regularly expressed in LP-HL,
may be used for the differentiation of LP-HL not only from
CHL, but also from TCRBCL.193
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